摘要
肝细胞肝癌(hepatocellular carcinoma,HCC)约占原发肝癌的75%~85%,是全球发病率较高的恶性肿瘤之一,免疫治疗目前被认为是较有前景的防治肝癌术后复发及病情进展的治疗手段。肝癌免疫治疗方案主要分为主动和被动免疫治疗,包括肿瘤疫苗、免疫检查点抑制剂和过继性免疫细胞输注治疗等。本文就近年肝癌免疫治疗的现状和研究进展进行概述。
Hepatocellular carcinoma (HCC) accounts for approximately 75%-85% of primary liver cancer cases and is one of the most frequently diagnosed malignancies worldwide. Immunotherapy is currently considered to be the most promising treatment to prevent the progression and postoperative recurrence of HCC. At present, the treatment strategies of immunotherapy for HCC are classified as active immunotherapy and passive immunotherapy, including tumor vaccine therapy, immune checkpoint inhibitors, and adoptive cell therapy. Here we review the current clinical progression and discuss the future perspective on immune therapy for HCC.
作者
唐雨豪
王骏成
朱应钦
陈锦滨
张耀军
周仲国
陈敏山
徐立
Yuhao Tang;Juncheng Wang;Yingqin Zhu;Jinbin Chen;Yaojun Zhang;Zhongguo Zhou;Minshan Chen;Li Xu(Ddepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2019年第9期441-446,共6页
Chinese Journal of Clinical Oncology
基金
国家自然科学基金项目(编号:81772589)
国家科技重大专项项目(编号:2018ZX10302205,2018ZX10723204)资助~~
关键词
肝细胞癌
免疫治疗
免疫检查点抑制剂
嵌合抗原受体T细胞
hepatocellular carcinoma (HCC)
immunotherapy
immune checkpoint inhibitors
chimeric antigen receptor T cell
